Fabtech Technologies Limited has submitted its investor presentation to the National Stock Exchange of India Limited and BSE Limited for the upcoming Investors/Analysts Meeting at CVOCA Investocraft 2026. The presentation was filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on February 27, 2026.

Meeting Details and Regulatory Compliance

The investor interaction is scheduled for February 28, 2026, from 8:30 a.m. (IST) onwards at Sahara Star, Vile Parle, Mumbai. The company has structured this as a group meeting with investors to be conducted in physical mode.

The notification was signed by Hemant Mohan Anavkar, Executive Director with DIN: 00150776. The company has emphasized that all discussions will be based on publicly available information only, with no unpublished price-sensitive information intended to be shared.

Strategic Market Positioning

The investor presentation positions Fabtech Technologies as India's Global Life Sciences Infrastructure Platform, focusing on engineering medicinal sovereignty across continents. The company highlights its role in the 15-year lifescience infrastructure buildout across GCC, Middle East & Africa and surrounding nations.

Market Opportunity and Financial Highlights

The presentation outlines a significant Total Addressable Market (TAM) across three key regions. The GCC market shows an estimated pharma capex of USD 40-50 billion for 2025-2040, driven by Saudi Vision 2030, UAE biotech initiatives, and localization mandates.

The company reports a current order book of approximately ₹926 crore as of January 31, 2026. Fabtech Technologies aims to improve its conversion rate from 10% to 20% post-European acquisition, which would double the hit rate on the same lead base.

Execution Capabilities and Strategic Presence

The presentation emphasizes Fabtech's integrated capabilities across process engineering, HVAC and containment systems, water systems, and in-house manufacturing leverage. The company operates through an ecosystem of subsidiaries including Fabtech Technologies LLC (UAE), TSA, and other specialized entities.

Fabtech Technologies has established benchmark projects including the first Egyptian flu vaccine project, largest IV solution facility in Saudi Arabia, and UAE's only USFDA approved facility. These projects create regulatory credibility and reference advantages in the competitive landscape.

Fabtech Technologies Limited has secured a major international contract worth USD 7.05 million from a West Africa-based company, as disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Contract Details

The company announced on February 14, 2026, that it has bagged this significant order for the supply, installation and commissioning of infrastructure for an Oral Solid Dosage (OSD) facility. The contract value stands at USD 7,050,000.00, which translates to approximately Rs. 63.6 crores.

Project Scope and Timeline

The contract encompasses a comprehensive agreement for the supply, installation and commissioning of infrastructure required for pharmaceutical manufacturing. The project is scheduled to be completed within 23-27 months from the date of receiving the advance payment from the client.

Confidentiality and Compliance

Due to confidentiality obligations, Fabtech Technologies has not disclosed the name of the West African client. The company has confirmed that this contract does not fall within related party transactions and that neither the promoter, promoter group, nor group companies have any interest in the entity that awarded the contract.

Strategic Significance

This international order represents a significant business development for Fabtech Technologies, demonstrating the company's capabilities in pharmaceutical infrastructure projects across global markets. The contract reinforces the company's position in the international pharmaceutical equipment and infrastructure sector, particularly in emerging markets like West Africa.